Drug Type Synthetic peptide |
Synonyms JSM 6427 |
Target |
Action antagonists |
Mechanism α5β1 antagonists(Integrin alpha-5/beta-1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glycogen Storage Disease Type II | Phase 1 | United States | 01 Sep 2007 | |
Wet age-related macular degeneration | Phase 1 | United States | 01 Sep 2007 | |
Vitreoretinopathy, Proliferative | Preclinical | Germany | 01 May 2007 | |
Retinopathy of Prematurity | Preclinical | Germany | 01 May 2006 |
Phase 1 | - | gwiextuqzp(lzmaqoenqo) = jukhplywem vhgtddtgey (kkurzdylxz ) | - | 01 Apr 2009 | |||
Phase 1 | - | eyorrkikzd(wlwpmtrvzt) = afnynvlqge ksptaxtmuu (xabebzfdif ) View more | Positive | 01 May 2008 |